Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowModerna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Moderna Inc. (MRNA)
Moderna is a biotech pioneering mRNA vaccines and therapeutics.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRNA news
- Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
- Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
- Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
- Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
- Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
